Actavis

The Medicines Company develops products that improve acute hospital care and meets the demands of some of the world's most advanced medical practitioners. The company markets Angiomax for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company utilizes its range of clinical and commercial skills to develop products acquired from leading life science innovators. In addition to the approved Angiomax product, The Medicines Company is developing clevidipine, a short-acting calcium channel blocker. The Medicines Company is also conducting significant clinical research to study potential additional indications for Angiomax use. In December of 2003, the Company acquired cangrelor, an anticoagulant that prevents platelet clotting factors from activating, which the company believes has potential uses in coronary angioplasty and cardiac surgery. The Medicines Company has offices in Parsippany, N.J., Waltham, Mass., and Abingdon, United Kingdom.

Stryker Orthopaedics develops, manufactures and markets a range of orthopaedic reconstructive products for patients throughout the world. It offers hip, knee, upper extremity, trauma and spinal systems. The company also provides bone cement and bone substitutes. Stryker Orthopaedics has offices in the United States, France and Ireland. It is a division of Stryker Corporation, which is one of the world's leading medical technology companies. Stryker Corporation s products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries. In addition, the parent company offers endoscopic, surgical navigation, communication and digital imaging systems. It has received the Gallup Great Workplace Award.